Aijun Qiao.jpg

Dr. Aijun Qiao was graduated with his PhD degree in Biochemistry and Molecular Biology from Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), Tsinghua University in China, and received his postdoctoral training from Feinberg Cardiovascular Research Institute, School of Medicine, Northwestern University at Chicago and Cancer Center of Augusta University at Augusta, respectively. After postdoctoral training, he joined the Department of Biomedical Engineering at the University of Alabama at Birmingham as Assistant Professor in June 2017. From September 2022, he joined Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences as Professor. Dr. Qiao has broad research experiences in Metabolic diseases and cardiovascular diseases, including Obesity, Type 2 diabetes (T2D), Non-alcohol fatty liver disease (NAFLD), Insulin resistance, Dyslipidemia and Atherosclerosis. His research mainly focuses on studying the molecular and pathological mechanism of these diseases and identifying novel therapeutic targets for drug development. Dr. Qiao has published over 34 original research articles which some are in top journals, such as Hepatology, Nature Communications, The Journal of Cell Biology, et al. He is reserving an editor board members and professional reviewers for numerous Journals.